MX2012003042A - Use of guaifenesin for inhibiting mucin secretion. - Google Patents

Use of guaifenesin for inhibiting mucin secretion.

Info

Publication number
MX2012003042A
MX2012003042A MX2012003042A MX2012003042A MX2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A
Authority
MX
Mexico
Prior art keywords
guaifenesin
mucin secretion
inhibiting mucin
inhibiting
secretion
Prior art date
Application number
MX2012003042A
Other languages
Spanish (es)
Inventor
Helmut Albrecht
Kim K Chul
Jeanclare Seagrave
Bruce K Rubin
Gail Solomon
Original Assignee
Reckitt Benckiser Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser Llc filed Critical Reckitt Benckiser Llc
Publication of MX2012003042A publication Critical patent/MX2012003042A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.
MX2012003042A 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion. MX2012003042A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
MX2012003042A true MX2012003042A (en) 2012-05-29

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003042A MX2012003042A (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion.

Country Status (12)

Country Link
EP (1) EP2475360A1 (en)
JP (1) JP2013504554A (en)
KR (1) KR20120068889A (en)
CN (1) CN102596189A (en)
AU (1) AU2010294008B2 (en)
BR (1) BR112012005517A2 (en)
CA (1) CA2773611A1 (en)
MX (1) MX2012003042A (en)
MY (1) MY161187A (en)
RU (1) RU2012114323A (en)
WO (1) WO2011030163A1 (en)
ZA (1) ZA201201822B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243857A1 (en) * 2012-04-06 2014-10-16 The Uab Research Foundation Methods for increasing CFTR activity
KR102211605B1 (en) * 2018-02-26 2021-02-04 대한민국 Methods for Screening Therapeutic Agents for Airway Conduct MucinSecretion Inhibitor Using the Frog Embryo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1471872A2 (en) * 2002-02-04 2004-11-03 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
CN1835942A (en) * 2003-06-19 2006-09-20 金纳莱公司 Mucin synthesis inhibitors
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
BR112012005517A2 (en) 2016-04-19
AU2010294008A1 (en) 2012-04-05
ZA201201822B (en) 2013-05-29
CA2773611A1 (en) 2011-03-17
JP2013504554A (en) 2013-02-07
CN102596189A (en) 2012-07-18
MY161187A (en) 2017-04-14
WO2011030163A1 (en) 2011-03-17
EP2475360A1 (en) 2012-07-18
KR20120068889A (en) 2012-06-27
RU2012114323A (en) 2013-10-20
AU2010294008B2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
HK1247133A1 (en) Low ether composition and delivery apparatus
EP2231133A4 (en) Method and compositions for administering resveratrol and pterostilbene
GB0906541D0 (en) Delivery method and compositions
HK1170679A1 (en) Compositions and methods for drug delivery
MX344786B (en) Compositions and methods for treating gaucher disease.
EP2512236A4 (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
EP2643045A4 (en) Therapeutic methods and compositions for solid delivery
EP2435057A4 (en) Compositions and methods for modulating lipid composition
EP2504025A4 (en) Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
EP2442655A4 (en) Compositions and methods for treating amyotrophic lateral sclerosis
HK1166280A1 (en) Composition for treatment of tuberculosis
EP2470019A4 (en) Compositions for delivery of insoluble agents
ZA201404187B (en) Compositions and methods for treating dental conditions
PL2385029T3 (en) Compositions and method for well cementing
IN2014CN04634A (en)
EP2429584A4 (en) Methods and compositions for treatment
HK1173373A1 (en) Method and composition for synchronizing time of insemination
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
EP2588132A4 (en) Methods and compositions for cns delivery of -galactocerebrosidase
HK1168511A1 (en) Anti-oxidant composition
EP2465512A4 (en) Pharmaceutical composition for suppressing pain
ZA201203060B (en) Composition and method of delivery
EP2694098A4 (en) Oral enzyme compositions for intestinal delivery
SG10201907649QA (en) Preventive or therapeutic agent for fibrosis
IL213105A0 (en) Dipeptidyl peptidase iv inhibitors